First Patient Enrolled in the Clinnova IBD Use Case at the Basel Site

• News & Media

On January 21, 2026, the first patient was successfully enrolled in the Clinnova Inflammatory Bowel Disease (IBD) use case at the Basel site. With this milestone, Basel begins its active contribution to the steadily growing IBD cohort across Clinnova partner institutions. Overall enrollment numbers across the consortium are now approaching 200 patients, reflecting strong recruitment momentum and coordinated efforts across sites.

The Basel contribution builds on the well-established IBD network in the Upper Rhine region. The site is led by the team of Prof. Jan Niess at Clarunis – Universitäres Bauchzentrum Basel, the leading gastroenterology (GI) center in Basel. Now fully integrated within the University Hospital Basel (USB), Clarunis further strengthens the clinical excellence and translational research capacity supporting the Clinnova initiative.

The enrollment of the first patient in Basel represents an important step in expanding the consortium’s real-world data foundation and further reinforces the strength of cross-border collaboration in translational research.

We thank the clinical, research, and data management teams for their dedication and continued commitment to the Clinnova vision.